RT Journal Article
SR Electronic
T1 Model-based evaluation of alternative reactive class closure strategies against COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.18.21255683
DO 10.1101/2021.04.18.21255683
A1 Liu, Quan-Hui
A1 Zhang, Juanjuan
A1 Peng, Cheng
A1 Litvinova, Maria
A1 Huang, Shudong
A1 Poletti, Piero
A1 Trentini, Filippo
A1 Guzzetta, Giorgio
A1 Marziano, Valentina
A1 Zhou, Tao
A1 Viboud, Cecile
A1 Bento, Ana I.
A1 Lv, Jiancheng
A1 Vespignani, Alessandro
A1 Merler, Stefano
A1 Yu, Hongjie
A1 Ajelli, Marco
YR 2021
UL http://medrxiv.org/content/early/2021/04/23/2021.04.18.21255683.abstract
AB There are contrasting results concerning the effect of reactive school closure on SARS-CoV-2 transmission. To shed light on this controversy, here we develop a data-driven computational model of SARS-CoV-2 transmission to investigate mechanistically the effect on COVID-19 outbreaks of school closure strategies based on syndromic surveillance and antigen screening of students. We found that by reactively closing classes based on syndromic surveillance, SARS-CoV-2 infections are reduced by no more than 13.1% (95%CI: 8.6%-20.2 %), due to the low probability of timely symptomatic case identification among the young population. We thus investigated an alternative triggering mechanism based on repeated screening of students using antigen tests. Should population-level social distancing measures unrelated to schools enable maintaining the reproduction number (R) at 1.3 or lower, an antigen-based screening strategy is estimated to fully prevent COVID-19 outbreaks in the general population. Depending on the contribution of schools to transmission, this strategy can either prevent COVID-19 outbreaks for R up to 1.9 or to at least greatly reduce outbreak size in very conservative scenarios about school contribution to transmission. Moving forward, the adoption of antigen-based screenings in schools could be instrumental to limit COVID-19 burden while vaccines continue to roll out through 2021, especially in light of possible continued emergence of SARS-CoV-2 variants.Competing Interest StatementAV reports grants from Metabiota inc., outside the submitted work. HY has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. MA has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.Funding StatementQ.-H.L. acknowledges funding from the National Natural Science Foundation of China (No.62003230), Chengdu Science and Technology Bureau (No.2020-YF05-00073-SN), the Fundamental Research Funds for the Central Universities (No.1082204112289), the Science and Technology Department of Sichuan Province (No.2020YFS0009). T.Z. acknowledge funding from the National Natural Science Foundation of China (No.11975071, No.61673085). P.P., F.T., G.G., V.M., and S.M. acknowledge funding from the European Union Grant 874850 MOOD (cataloged as MOOD 000). H.Y. acknowledge funding from the National Science Fund for Distinguished Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and Technology Committee (No 20411950100). M.L., A.V., and M.A. acknowledge funding from the Cooperative Agreement number NU38OT000297 from the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modelling study that requires no ethical review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript can be requested from the corresponding authors.